Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer-Reference-Cited by-同舟云学术

Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer

Published:2017-10-31 Issue:5 Volume:142 Page:1056-1066
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Matsuzaki Satoko¹²,Serada Satoshi²³,Hiramatsu Kosuke²³,Nojima Satoshi⁴,Matsuzaki Shinya¹,Ueda Yutaka¹,Ohkawara Tomoharu²³,Mabuchi Seiji¹,Fujimoto Minoru²³,Morii Eiichi⁴,Yoshino Kiyoshi¹,Kimura Tadashi¹,Naka Tetsuji²³^ORCID

Affiliation:

1. Department of Obstetrics and GynecologyOsaka University Graduate School of MedicineYamadaoka Suita Osaka Japan

2. Laboratory of Immune SignalNational Institutes of Biomedical Innovation, Health and NutritionIbaraki Osaka Japan

3. Center for Intractable Immune Disease, Kochi Medical School, Kochi UniversityNankoku Kochi Japan

4. Department of PathologyOsaka University Graduate School of MedicineYamadaoka Suita Osaka Japan

Funder

Japan Agency for Medical Research and Development, AMED (Research on Development of New Drugs)

Japanese Ministry of Education, Science, Sports, and Culture Grant-in-Aid for Scientific Research (C)

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.31124

Reference33 articles.

1. Global cancer statistics, 2012

2. Antibody-Drug Conjugates in Cancer Therapy

3. Antibody Drug Conjugates for Cancer Therapy

4. Brentuximab Vedotin (SGN-35)

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glypican-1-targeted antibody–drug conjugate inhibits the growth of glypican-1-positive glioblastoma;Neoplasia;2024-04

2. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis;Advanced Science;2024-01-10

3. Advances in targeted therapy for pancreatic cancer;Biomedicine & Pharmacotherapy;2023-12

4. Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with⁸⁹Zr or²¹¹At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma;Journal of Nuclear Medicine;2023-10-12

5. Glypican1: A potential cancer biomarker for nanotargeted therapy;Drug Discovery Today;2023-08